Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver Axis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Endo, Hitoshi ^a   Niioka, Maki ^a   Kobayashi, Noriko ^b   Tanaka, Mamoru ^b   Watanabe, Tetsu ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Miyarisan Pharmaceutical Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BUTYRIC ACID; CHOLINE; ENDOTOXIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; MIYAIRI 588; OCCLUDIN; PROBIOTIC AGENT; PROTEIN KINASE B; PROTEIN ZO1; SERINE; SIRTUIN 1; SMALL INTERFERING RNA; TIGHT JUNCTION PROTEIN; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INTESTINE; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER FIBROSIS; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; UBIQUITINATION;

ANIMALS; BLOTTING, WESTERN; BUTYRATES; FATTY LIVER; HEP G2 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER; MALE; PROBIOTICS; RATS; RATS, INBRED F344; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE;

EID: 84877798095     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063388     Document Type: Article

References (64)

1. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185.
2. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873.
3. Hashimoto E, Tokushige K, (2011) Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 46Suppl 1: 63-69.
4. Musso G, Gambino R, Cassader M, (2010) Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol 21: 76-83.
5. Tilg H, Moschen AR, (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52: 1836-1846.
6. Szabo G, Bala S, Petrasek J, Gattu A, (2010) Gut-liver axis and sensing microbes. Dig Dis 28: 737-744.
7. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, et al. (2007) Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292: G518-525.
8. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481.
9. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, et al. (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49: 1877-1887.
10. Musso G, Gambino R, Cassader M, (2009) Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48: 1-26.
11. Kumar A, Wu H, Collier-Hyams LS, Kwon YM, Hanson JM, et al. (2009) The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol 182: 538-546.
12. Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, et al. (2003) Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int 45: 86-90.
13. Okamoto T, Sasaki M, Tsujikawa T, Fujiyama Y, Bamba T, et al. (2000) Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol 35: 341-346.
14. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI, (2011) Human nutrition, the gut microbiome and the immune system. Nature 474: 327-336.
15. Wachtershauser A, Stein J, (2000) Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr 39: 164-171.
16. Vernia P, Annese V, Bresci G, d'Albasio G, D'Inca R, et al. (2003) Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 33: 244-248.
17. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, et al. (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58: 1509-1517.
18. Long YC, Zierath JR, (2006) AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116: 1776-1783.
19. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13: 376-388.
20. Li XN, Song J, Zhang L, LeMaire SA, Hou X, et al. (2009) Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes 58: 2246-2257.
21. Peng L, Li ZR, Green RS, Holzman IR, Lin J, (2009) Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139: 1619-1625.
22. Endo H, Niioka M, Sugioka Y, Itoh J, Kameyama K, et al. (2011) Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats. Pathobiology 78: 239-252.
23. Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, et al. (2009) c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 137: 1467-1477 e1465.
24. Watanabe T, Niioka M, Hozawa S, Kameyama K, Hayashi T, et al. (2000) Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J Hepatol 33: 224-235.
25. Watanabe T, Niioka M, Ishikawa A, Hozawa S, Arai M, et al. (2001) Dynamic change of cells expressing MMP-2 mRNA and MT1-MMP mRNA in the recovery from liver fibrosis in the rat. J Hepatol 35: 465-473.
26. Okada K, Warabi E, Sugimoto H, Horie M, Tokushige K, et al. (2012) Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis. J Gastroenterol 47: 924-935.
27. Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, et al. (2010) Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 298: G283-294.
28. Lavina B, Gracia-Sancho J, Rodriguez-Vilarrupla A, Chu Y, Heistad DD, et al. (2009) Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut 58: 118-125.
29. Minamiyama Y, Takemura S, Kodai S, Shinkawa H, Tsukioka T, et al. (2010) Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol Endocrinol Metab 298: E1140-1149.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
31. Morino S, Kondo T, Sasaki K, Adachi H, Suico MA, et al. (2008) Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling. PLoS One 3: e4068.
32. Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, et al. (2004) AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279: 47898-47905.
33. Endo H, Sugioka Y, Nakagi Y, Saijo Y, Yoshida T, (2008) A novel role of the NRF2 transcription factor in the regulation of arsenite-mediated keratin 16 gene expression in human keratinocytes. Environ Health Perspect 116: 873-879.
34. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
35. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
36. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
37. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, et al. (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275: 16023-16029.
38. Weerachayaphorn J, Cai SY, Soroka CJ, Boyer JL, (2009) Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression. Hepatology 50: 1588-1596.
39. Houtkooper RH, Pirinen E, Auwerx J, (2012) Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13: 225-238.
40. Wang RH, Kim HS, Xiao C, Xu X, Gavrilova O, et al. (2011) Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest 121: 4477-4490.
41. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
42. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, et al. (2009) Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50: 1094-1104.
43. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, et al. (2009) VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49: 989-997.
44. Bergheim I, Weber S, Vos M, Kramer S, Volynets V, et al. (2008) Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 48: 983-992.
45. Miyoshi M, Sakaki H, Usami M, Iizuka N, Shuno K, et al. (2011) Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin Nutr 30: 252-258.
46. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, et al. (2010) Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 464: 1313-1319.
47. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056-1060.
48. Nasrin N, Kaushik VK, Fortier E, Wall D, Pearson KJ, et al. (2009) JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One 4: e8414.
49. Sasaki T, Maier B, Koclega KD, Chruszcz M, Gluba W, et al. (2008) Phosphorylation regulates SIRT1 function. PLoS One 3: e4020.
50. Koketsu Y, Sakoda H, Fujishiro M, Kushiyama A, Fukushima Y, et al. (2008) Hepatic overexpression of a dominant negative form of raptor enhances Akt phosphorylation and restores insulin sensitivity in K/KAy mice. Am J Physiol Endocrinol Metab 294: E719-725.
51. Horike N, Sakoda H, Kushiyama A, Ono H, Fujishiro M, et al. (2008) AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver. J Biol Chem 283: 33902-33910.
52. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, et al. (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279: 1304-1309.
53. Amato S, Liu X, Zheng B, Cantley L, Rakic P, et al. (2011) AMP-activated protein kinase regulates neuronal polarization by interfering with PI 3-kinase localization. Science 332: 247-251.
54. Schenk S, McCurdy CE, Philp A, Chen MZ, Holliday MJ, et al. (2011) Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. J Clin Invest 121: 4281-4288.
55. Zinzalla V, Stracka D, Oppliger W, Hall MN, (2011) Activation of mTORC2 by association with the ribosome. Cell 144: 757-768.
56. Garcia-Trevijano ER, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, et al. (1999) Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 29: 960-970.
57. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, et al. (2010) Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48: 357-371.
58. Liu GH, Qu J, Shen X, (2008) NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim Biophys Acta 1783: 713-727.
59. Sakai M, Muramatsu M, (2007) Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis. Biochem Biophys Res Commun 357: 575-578.
60. Ikeda H, Nishi S, Sakai M, (2004) Transcription factor Nrf2/MafK regulates rat placental glutathione S-transferase gene during hepatocarcinogenesis. Biochem J 380: 515-521.
61. Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, et al. (2003) Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35: 238-245.
62. Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Kaneko H, et al. (2009) The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 29: 493-502.
63. Liu XM, Peyton KJ, Shebib AR, Wang H, Korthuis RJ, et al. (2011) Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival. Am J Physiol Heart Circ Physiol 300: H84-93.
64. Sakamoto K, Iwasaki K, Sugiyama H, Tsuji Y, (2009) Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell 20: 1606-1617.